As previously reported, the LYNX-1 Phase 3 study met its primary endpoint, with a statistically significant greater percentage of Phentolamine Ophthalmic Solution 0.75%-treated participants gaining 15 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback